Acadia Pharmaceuticals Up 25.5% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Thu Sep 25, 9:14AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 4 months, Acadia Pharmaceuticals has returned 25.51% as of today's recent price of $26.69.
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 29.1% (ACAD)
Comtex SmarTrend(R) - Wed Sep 17, 4:48PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 4 months, Acadia Pharmaceuticals has returned 29.09% as of today's recent price of $27.45.
Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH
at The Street - Fri Sep 12, 5:00AM CDT
Arcadia Pharmaceuticals and Isis Pharmaceuticals are the next big biotech takeover targets, Cramer says.
Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.
Acadia Pharmaceuticals Shares Up 28.6% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Sep 10, 11:05AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 3 months, Acadia Pharmaceuticals has returned 28.62% as of today's recent price of $27.35.
Breakthrough Therapy Designation, Outlook Affirmation, Conference Presentation, Sales Data, and Submarine Delivery - Research Reports on ACADIA, Boeing, United Tech, Caterpillar and General Dynamics
PR Newswire - Fri Sep 05, 7:35AM CDT
Today, Analysts Review released its research reports regarding ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), The Boeing Company (NYSE: BA), United Technologies Corp. (NYSE: UTX), Caterpillar Inc. (NYSE: CAT) and General Dynamics Corp. (NYSE: GD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6239-100free.
VUG, UPRO, ACAD, SNI, TNA, BLIN Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Sep 05, 3:36AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vanguard Growth Index Fund (NYSE:VUG), ProShares UltraPro S&P 500 (NYSE:UPRO), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Scripps Networks Interactive Inc (NYSE:SNI), Direxion Daily Small Cap Bull 3X Shares (NYSE:TNA), Bridgeline Digital Inc (NASDAQ:BLIN) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Delta and Office Depot are big market movers
AP - Wed Sep 03, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Critical Alerts For Activision Blizzard, ACADIA Pharmaceuticals, Shutterstock, Lockheed Martin and Orexigen Therapeutics Released By InvestorsObserver
PR Newswire - Wed Sep 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ATVI, ACAD, SSTK, LMT and OREX.
After Yesterday's Rally of 10.97% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Sep 02, 5:23PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $25.20 to a high of $27.12. Yesterday, the shares gained 11.0%, which took the trading range above the 3-day high of $24.20 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today
at The Street - Tue Sep 02, 1:38PM CDT
ACADIA Pharmaceuticals (ACAD) shares are up double digits on Tuesday after its Parkinson's disease treatment was designated as a Breakthrough Therapy by the FDA
Compuware Climbs On Buyout Announcement
at The Street - Tue Sep 02, 12:34PM CDT
Compuware Corporation (NASDAQ:CPWR), Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) are among today's top gainers on the stock market midday. Postin...
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID(TM) (Pimavanserin) for Parkinson's Disease Psychosis
Business Wire - Tue Sep 02, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID(TM) (pimavanserin) for the treatment of Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinson's disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application (NDA). ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID(TM) for Pimavanserin
Business Wire - Thu Aug 28, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous disorders, today announced that the U.S. Food and Drug Administration (FDA) has provisionally accepted the trade name "NUPLAZID"
Acadia Pharmaceuticals Has Returned 11.5% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Aug 27, 9:31AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 3 months, Acadia Pharmaceuticals has returned 11.50% as of today's recent price of $23.71.
Earnings Look Back: Acadia Pharmaceuticals Is Up 6.7% Since Reporting Quarterly Results 2 Weeks Ago (ACAD)
Comtex SmarTrend(R) - Mon Aug 25, 7:21AM CDT
When Acadia Pharmaceuticals (NASDAQ:ACAD) reported earnings two weeks ago on August 5th, 2014, analysts, on average, expected the company to report a loss of $0.13 on sales of $388.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.22 per share on sales of $28.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Acadia Pharmaceuticals have climbed from $20.77 to $22.17, representing a gain of 6.7% since the company reported earnings 20 days ago.
Technical Data on Biotech Equities -- Aegerion Pharma, ACADIA Pharma, Inovio Pharma, Curis, and Seattle Genetics
PR Newswire - Wed Aug 20, 8:20AM CDT
On Tuesday, August 19, 2014, the NASDAQ Composite ended at 4,527.51, up 0.43%, the Dow Jones Industrial Average advanced 0.48%, to finish the day at 16,919.59, and the S&P 500 closed at 1,981.60, up 0.50%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.42, up 0.66%, with the index also advancing 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Curis Inc. (NASDAQ: CRIS), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at:
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Post Earnings Update: Acadia Pharmaceuticals Has Climbed 8.8% Higher in Past Week (ACAD)
Comtex SmarTrend(R) - Mon Aug 18, 9:08AM CDT
A week ago on August 5th, 2014 Acadia Pharmaceuticals (NASDAQ:ACAD) reported earnings and analysts, on average, expected a loss of $0.13 on sales of $388.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.22 per share on sales of $28.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Acadia Pharmaceuticals have climbed from $20.77 to $22.59, representing a gain of 8.8% since the company reported earnings 13 days ago.